Vaccines Associated with Guillain-Barré Syndrome
Influenza vaccines and meningococcal conjugate vaccine (MenACWY-D) have the most established associations with GBS, though the absolute risk remains very low at approximately 1-2 additional cases per million vaccinated persons.
Primary Vaccines with GBS Association
Influenza Vaccines
The influenza vaccine carries the most consistent evidence for GBS association, with an estimated risk of approximately 1 additional case per 1 million persons vaccinated 1. The risk appears similar across seasonal influenza vaccines and the 2009 H1N1 monovalent vaccines 1. GBS cases typically peak around 2 weeks post-vaccination 2, 3.
Important context: The 1976 swine influenza vaccine had a substantially higher GBS risk, but subsequent influenza vaccines have shown much lower or no increased risk 2, 4. Some UK studies found no association or even decreased GBS risk after influenza vaccination, though this may reflect "healthy vaccinee" effects 1.
Meningococcal Conjugate Vaccine (MenACWY-D)
Shortly after licensure in 2005, several GBS cases were reported with symptom onset clustering around 14 days post-vaccination 5. A large retrospective study of 1.4 million vaccinated adolescents estimated the attributable risk at 0 to 1.5 additional cases per million vaccines within 6 weeks 5.
Notably, no GBS cases were reported with MenACWY-CRM (the alternative meningococcal conjugate vaccine) 5, and VSD surveillance found no GBS cases within 42 days of 889,684 MenACWY-D doses 5.
COVID-19 Vaccines (Recent Evidence)
Recent multinational data shows:
- ChAdOx1-S (Vaxzevria/Covishield): Increased risk (RI = 3.10) 6
- Ad26.COV2.S (Janssen): Significantly elevated reporting rates (3.29-4.07 per million doses within 21-42 days) with observed-to-expected ratios of 2.34-3.79 7
- mRNA vaccines (BNT162b2, mRNA-1273): Either no increased risk or potentially decreased risk 6, 7
Other Vaccines with Historical Concerns
Tetanus toxoid-containing vaccines: Earlier IOM reviews suggested a possible causal association 8, though more recent large epidemiological studies found no correlation 4.
Oral polio vaccine (OPV): Previously considered to have a possible association 8, but recent mass immunization campaigns found no correlation 4.
Rabies vaccine: Older mammalian brain tissue-cultured vaccines showed increased GBS risk, but newer chick embryo cell-derived formulations do not 4.
Hepatitis B vaccine: The second-highest number of GBS reports (n=94) in VAERS data from 1990-2005, with higher incidence in those <65 years 9.
RSV vaccines: Post-marketing surveillance has confirmed increased GBS incidence, raising emerging concerns particularly in adults >65 years 10.
Clinical Management Algorithm
For Patients WITHOUT Prior GBS History:
- Proceed with indicated vaccinations - the benefits substantially outweigh the minimal GBS risk for all vaccines except possibly Ad26.COV2.S
- No special precautions needed beyond standard vaccine administration protocols
For Patients WITH Prior GBS History:
If GBS occurred within 6 weeks of previous influenza vaccination:
- Low-risk patients (not at high risk for severe influenza): Generally avoid influenza vaccination; consider antiviral chemoprophylaxis instead 1, 11
- High-risk patients (at risk for severe influenza complications): Benefits likely outweigh risks - proceed with vaccination 1
If GBS occurred >6 weeks after vaccination or unrelated to vaccination:
- Proceed with indicated vaccinations - the temporal relationship makes vaccine causation unlikely
For meningococcal vaccines:
- As of 2010, ACIP removed the precaution for persons with GBS history because benefits outweigh recurrence risk 5
- History of GBS remains listed as a precaution in package inserts but is not a contraindication
Critical Caveats
- Background GBS incidence is 0.75-2 cases per 100,000 persons annually 1, making temporal coincidence common
- Persons with prior GBS have substantially higher likelihood of recurrent GBS regardless of vaccination 1
- GBS is more strongly associated with infections (particularly Campylobacter jejuni and respiratory infections) than with vaccines 1, 2, 12
- SARS-CoV-2 infection itself carries increased GBS risk (RI = 3.35) 6
- Among vaccine-associated GBS cases, death occurs in ~3% and disability in ~17%, comparable to general GBS population rates 9